Eton Pharmaceuticals Inc (ETON)
6.97
+0.06
(+0.87%)
USD |
NASDAQ |
Oct 04, 16:00
6.97
0.00 (0.00%)
After-Hours: 19:17
Eton Pharmaceuticals SG&A Expense (TTM): 19.66M for June 30, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
June 30, 2024 | 19.66M |
March 31, 2024 | 18.74M |
December 31, 2023 | 18.93M |
September 30, 2023 | 18.71M |
June 30, 2023 | 18.54M |
March 31, 2023 | 19.13M |
December 31, 2022 | 18.58M |
September 30, 2022 | 17.95M |
June 30, 2022 | 17.08M |
March 31, 2022 | 15.04M |
December 31, 2021 | 14.30M |
September 30, 2021 | 14.23M |
Date | Value |
---|---|
June 30, 2021 | 14.36M |
March 31, 2021 | 14.06M |
December 31, 2020 | 12.61M |
September 30, 2020 | 11.39M |
June 30, 2020 | 9.584M |
March 31, 2020 | 8.573M |
December 31, 2019 | 7.552M |
September 30, 2019 | 6.307M |
June 30, 2019 | 5.513M |
March 31, 2019 | 4.593M |
December 31, 2018 | 4.694M |
September 30, 2018 | 4.716M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
7.552M
Minimum
Dec 2019
19.66M
Maximum
Jun 2024
15.21M
Average
15.04M
Median
Mar 2022
SG&A Expense (TTM) Benchmarks
Biomarin Pharmaceutical Inc | 987.94M |
Integra Lifesciences Holdings Corp | 686.35M |
Elutia Inc | 28.48M |
Immuneering Corp | 16.62M |
Journey Medical Corp | 37.22M |